# Synvida

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synvida

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.synvida-bio.com
- Total disclosed funding: $28M
- Latest round: Series A (Jan 10, 2024)
- Investors on record: 2

## About

Based in Shanghai, China, and founded in 2021, Synvida is a biopharmaceutical company focusing on drug research and development in the fields of coagulation and fibrosis. The founder, Junling Liu is a vice chairman of the Society of Vascular Medicine - Chinese Association of Pathophysiology. In December 2023, the IPF treatment antibody clinical trial application was approved by CDE (Center for Drug Evaluation). In January 2024, Synvida raised series A funding for approximately CNY 200 million.

The company is committed to establishing original targets and molecular pipelines in the field of coagulation such as pulmonary fibrosis, thrombocytopenia, hemophilia, and thrombotic diseases. It has developed the EMPRESS system for constructing fully synthetic bacteriophages and yeast libraries.

The company will use the series A funds to promote the clinical and preclinical research of the company's pipelines.

## Funding rounds

- Series A, Jan 10, 2024, $28M — Lapam Capital, Shanghai Biomedical Fund

## Investors

- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- Shanghai Biomedical Fund — Series A